Maelor plc, the specialist critical care pharmaceuticals and devices

Volplex A 4% solution of succinylated gelatin used in operating theatres and wards in patients who require fluid replacement.
OptiFlo UK brand of a range of catheter irrigation solutions.
ContiSol international brand of a range of catheter irrigation solutions.

Development products

Micelle nanotechnology - A drug delivery system which enables insoluble active pharmaceuticals to be solubilised.
Lead development products in this area relate to:
* Interstitial cystitis and chronic pelvic pain (Plethora Solutions)
* Wound care
* Anaesthesiology

Operational highlights announced 1 June 2006

Licensing agreement with Plethora Solutions plc for micelle nanotechnology drug delivery system for use in the treatment of interstitial cystitis and painful bladder syndrome
Volplex UK rights re-acquired and product re-launched successfully. In-market sales for the second half of the year up 35% compared to the first half compared to the first half
OptiFlo UK in-market sales grow by 32% over the previous year
Jump 17%
http://www.maelor.plc.uk

10 May 2007 - Acquisition of Acorus Therapeutics Ltd completed

24 Feb 2004 - signed a major contract for the distribution of
its plasma substitute product,Volplex, in China. The agreement with Helicon Group
Pty Ltd will lead to Volplex being marketed and distributed in China through a network
of sales offices. Helicon is also charged with the regulatory submission, which should
be completed in 2004.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).

Volplex has expanded its international franchise over the last few months,
gaining regulatory approval in Argentina in December 2003 where it will shortly
be launched. Maelor has established partners in South Africa and Bangladesh
(where regulatory applications have already been submitted) and also in
Australia in preparation for future launches in those markets.

Steady rise up to 18% today

......up to 23.5% ??

Has it been tip somewhere? Has anyone got any news?

take over target and why not!

Pretty damn quiet.....has the lack of newsflow made us silent?

Well, I bought some at just under 11p. At today's price the investment risk is pretty small and the up-side remains as -ever.
Oddly, my purchase was recorded as a sale, in Trades-section.

No significant improvement in the sp but maybe (just) they are getting to grips with costs and (might) soon produce a profit. In that case the sp can be valued and one would hope that the profit might be slightly ahead.
Presently, turnover is almost the same as loss - so for every order they ship the loss increases by the same amount. Really does look as though Management hasn't really got to grips with the business.
The good thing, however, is they aren't a 1-product company - phew, that's OK then? Well, maybe.
( Annual accounts just received, hence the mind playing tricks)
Pity the AGM is in Wrexham, N Wales. Shan't be going and I doubt if many others will either.

So whats going on here... 1.75p rise... from 10p today morning to 11.75! and plenty of crazy buying continues.....

Speculative punt at these levels.

Market cap 3mil.

Cash balances half of market cap and they have increased lately.

Chairmans last statement :

Commenting on the results Chairman, Alastair Macpherson, said:

'These results, with strong revenue growth and sharply reduced losses, show that
Maelor is on track for profitability. With our two lead products continuing to
take market share and our products entering new territories, we expect to
continue to build on the substantial growth which we have achieved over the past
three years.'

There's a lot lot worse companies out there valued at 3mil.

Others seem to agree, 150k buys today and very little
selling but no move which is surprising.

Cannot believe there was not even one trade today !

The stock should be trading higher than 10p given their
strong cash position and long term prospects.

Thinking about going in on this one... now showing signs of recovery ? anyone any news & views?

Bought in this morning at 11.38p... onwards and upwards...no target in mind but would settle for 50% rise in next few months or 100% in a year!

We should ee some interesting annoucements and progress within the next few months. Definately an undervalued find and a serious consideration for any portfolio.

Totally new progressive management team looking to exapnd on MLR's traditional territory

I'm staying in and hoping for the best... might even top up at these levels !

Anyone know what's brewing ? sp is moving up fast-ish...
Now half way back to my breakeven price.

This looks to me like a lunchtime rise, caused by the mm's, due to fall back after 2.00pm

Scotland on Sunday-17Sept
Maelor looks healthy
PERRY GOURLEY

SHARES in healthcare group Maelor, which specialises in drugs and devices for patients in intensive care, appear to be showing signs of moving off the critical list themselves.

Last month they hit an all-time low of under 6p compared to the highs of over 120p seen five years ago.

But since then investors have been told that current trading was encouraging and it was making good progress with its new strategy. Its AGM heard that the board was "looking forward to the future with confidence" and a series of deals by the top men at the company appears to confirm that.

On September 8, chairman Geoff McMillan bought 200,000 at 6.6p and three days later chief executive Tim Wright bought 450,000 shares at 7p. Although the amount spent by the two hardly implies they are putting their houses on the line, they have each significantly increased their holdings. McMillan now holds 500,000 shares and Wright 450,000.

slmchow... good info... thanks... just need a bit of patience with this one to reap the rewards...

Looking good.... from the Sunday Times article...

"I have reinvested the cash, and a bit more, in a tiny healthcare firm called Maelor. This is a turnround play. Historically, Maelor had eggs in too many baskets. But new management came in a year ago, axed an expensive drug project and decided to focus on critical-care products. Only the house broker, Numis, gives it any coverage.

With a market value of only 3m and 1m in cash, there is all to play for. The chief executive, Tim Wright, has done it all before; he built the European operation of the Irish pharma giant, Elan Corporation, from nothing to a business with a 100m turnover. He and other directors bought 1.25m shares in Maelor last month, paying between 6.625p and 8p a share. Coming only three weeks before the company enters its closed period ahead of results when no director can deal that is a positive signal if ever there were one."

Results in about 3 months time

Anyone interested on the report by Lewis Charles Securities on Maelor dated 02/11/06 can go here

http://www.lewischarles.com/

Click on then , accept the legal disclaimer, then scroll down to . The report you want is the only one available at present.

Note: you will have to set your browser to accept pop-ups to be able to access the report.

looks like a nice little earner eh 'enry!

Anyone else in MLR ?

This from yesterday's Peter Shearlocks Small Cap Stock Picks

Transforming deal for Maelor

I tipped critical care products business Maelor last September (at 6.5p) for one reason only: its management had form for building a big pharma business from scratch. That faith appears to have been well placed. Maelor has now achieved a transforming deal with the acquisition of Acorus Therapeutics for up to 13 million. Acorus is in similar areas of neurology and critical care with products that have either been launched on the market or are at a late stage in their development therefore representing low-risk investments.

The deal transforms Maelors profit and loss account. In a trading statement on Thursday it said the final quarter of the year had sustained the upturn noted in the half-year statement and losses would be significantly below expectations. The blood plasma substitute Volplex is clearly still gaining market share. Together with Acorus, which is highly profitable, it looks as if the enlarged Maelor should make a profit of somewhere well over 1 million this year.

To help fund the deal, Maelor placed 80 million new shares at 10p on Thursday, lifting the number of shares in issue to 125 million. With the shares trading at 13.25p after the deal, that puts a value of 16.6 million on the company. There is clearly still a fair amount of upside. Continue to hold. I am a shareholder in Maelor.

After today's EGM I would expect to see some good press over the weekend as this appears to be a star in the making.

Now well in profit after the reverse takeover and with an easily manageable debt and good income flow this should be an interesting, and profitable ride, for the asute punter.

been in for a while now at 11pish so looking fwd to good times

I think that they will soon begin to roll!

Interesting. I am a shareholder in Plethora (PLE), although becoming increasingly disturbed by the failure of the company to produce the big deal for their PE product that was causing so much excitement a while back.

Here's a chart for MLR:

I bought into PLE in October '05 and sold for my Christmas box the same year. I think it has a little further to fall still and its on my watch list.

Meanwhile I expect MLR to rocket no exaggeration I mean rocket. But dont follow me, look at it yourselves.

Just out of interest and for those who have not seem this:-

Maelor plc

Maelor and Plethora Solutions enter into a licensing agreement for micelle nanotechnology
June 1st 2006 - Maelor Pharmaceuticals PLC (Maelor; AIM:MLR), the specialist critical care company, and Plethora Solutions Holdings PLC (Plethora or the Company, AIM : PLE), a UK-based speciality pharmaceutical company, are pleased to announce that Maelor has granted Plethora a licence to Maelors micelle nanotechnology delivery system.

Under the terms of the agreement, Maelor will provide Plethora with a worldwide, exclusive licence to Maelors micelle formulation nanotechnology, for application in Plethoras PSD597 programme for the treatment of interstitial cystitis and painful bladder syndrome (IC/PBS).

Plethora will be responsible for product development and the licence agreement is based upon an upfront payment, development and sales milestones and royalties to Maelor.

Micelle nanotechnology entraps drug compounds inside minute particles built up from polymers. This formulation technique can potentially deliver effective concentrations of drugs which would otherwise be insoluble in aqueous solution. The micelles may also protect the entrapped drug from hydrolysis by enzymes or protect the drug from extreme pH environments and thus enable more drug to be delivered to its site of action.

Plethora has already completed clinical pilot studies which indicated that its proprietary treatment, PSD597, can result in symptomatic relief from IC/PBS. Plethora recently announced that it had initiated a Phase II, double-blind, placebo-controlled clinical study in up to 20 centres in the US and Canada, with preliminary results anticipated at towards the end of 2006. In this study, PSD597 is being delivered locally into the bladder in a procedure conducted in an out-patient clinic. Following successful completion of this study, the micelle technology will be incorporated into the next stage of development and may open up the potential for patients to self administer treatments for interstitial cystitis.
IC/PBS is a condition characterised by chronic pelvic pain and afflicts up to two million women in the United States and Europe. The causes of IC/PBS are unknown and the few available approved treatments fail to bring about immediate and long-lasting symptomatic relief.

Maelor plc

Tim Wright, Chief Executive Officer of Maelor, commented:
As a specialist urology company with expertise in the clinical development of an IC/PBS treatment, Plethora is ideally placed to develop an effective and convenient micelle-based product for this debilitating condition and we are pleased to build upon their proprietary position in this area by providing access to our micelle nanotechnology.

Steven Powell, Chief Executive Officer of Plethora, commented:
Maelors micelle delivery technology is an ideal enhancement for this product, potentially broadening the patient population for this much needed treatment which has unique benefits for IC/PBS sufferer.

Enquiries:
Maelor plc
Tim Wright, CEO Tel: 01978 810153
Financial Dynamics
Ben Atwell/John Gilbert Tel: 020 7831 3113
Plethora Solutions
Steven Powell
Tel : 0207 269 8630
Buchanan Communications
Isabel Podda
Tel : 0207 466 5000

Notes to Editors:
A
bout Maelor:
Maelor plc is a specialist critical care pharmaceuticals and devices company. The company commercialises its critical care portfolio directly in the UK and commercialises early stage technology and non-core products through effective relationships with partners. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:MLR) Further information is available at www.maelor.plc.uk

About Plethora:
Plethora is focused on the development of products for the treatment of urological disease. The Company has products in clinical development for the treatment of overactive bladder, benign prostatic hyperplasia, stress urinary incontinence, interstitial cystitis and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based speciality sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) Further information is available at www.plethorasolutions.co.uk

And this one----
RNS Number:4720U Maelor PLC 05 April 2007

5 April 2007


Maelor plc ("Maelor" or the "Company")
Pre-Close Statement and Trading update


The Board of Maelor plc (AIM:MLR), the specialist critical care company is pleased to announce that it expects the outcome for the full year to 31st March 2007 to be ahead of current market expectations.

The positive trading highlighted at the Company's Interim Results on 2nd November 2006 has been sustained into the last quarter of the financial year and the Board anticipates a significant reduction in losses for the second half of the financial year. The sales growth of Volplex, a plasma substitute product, the commercialisation of which has been taken in-house, has continued, driven by active promotion and successful tendering for regional contracts. Sales of catheter flushing devices also continue to progress well.

The Company is actively building its specialist critical care portfolio having recently further added to its "specials" portfolio a fluid and volume replacement product as well as AquiHex, a product that the Company has developed, for use in hospital infection control. In parallel, late stage development of its complementary plasma substitute product, ISOplex, is progressing to schedule with approval still targeted for late 2008.

Commenting on the Company's performance Tim Wright CEO said:

"We are very pleased with the progress that Maelor has made since the strategic review in June 2006. In line with our new strategy the business is now focused, stabilised and well positioned for rapid organic and acquisitive growth. The acquisition of Acorus announced separately today represents a further step in our strategy to establish a significant business in hospital specialist medicine"


Ends -
For further information, call:

Tim Wright, Maelor plc - 01244 625150

Billy Clegg/Edward Westropp, Financial Dynamics - 020 7831 3113

Matthew Hall, Noble & Company - 020 7763 2200


This information is provided by RNS
The company news service from the London Stock Exchange

information.


Maelor First Day of Dealings


RNS Number:1874W
Maelor PLC
08 May 2007

8 May 2007




Maelor plc ("Maelor" or the "Company")

Re-Admission, Conditional Placing and Acquisition



The Board of Maelor plc (AIM: MLR), the specialist critical care company, is
pleased to announce that it has conditionally raised #8 million through a
placing of 80,000,000 new ordinary shares of 10p (the "Placing") by Noble &
Company Limited, Maelor's nominated adviser and broker.


Geoff McMillan, Non-Executive Chairman, Tim Wright, Chief Executive Officer,
Nigel Goldsmith, Finance Director, Ann Hardy, Executive Director and John
Gregory, Non-Executive Director have all participated in the Placing.


First Admission and the commencement of dealings in relation to the 70,005,833
Existing Ordinary Shares and New VCT/EIS Shares will take place today. It is
expected that Second Admission and the commencement of dealings in relation to
the 44,275,000 Protected VCT Shares and Non-VCT Shares will occur at 8am on 9
May 2007 and that Third Admission and commencement of dealings in relation to
10,000,000 Consideration Shares will occur at 8am on 10 May 2007. It is expected
that completion of the acquisition of Acorus Therapeutics Limited will occur
immediately following Third Admission.


Following completion of the acquisition of Acorus Therapeutics Limited, the
Company will have 124,280,833 ordinary shares of 10p in issue.


Tim Wright, CEO of Maelor said:


"The acquisition of Acorus is a transforming transaction for Maelor, creating a
strong, profitable business with positive cash flow. The integration risks,
costs and distractions are minimal due to the virtual nature of Acorus and the
combined product portfolios offer a high degree of synergy in terms of customer
base and distribution channels. We now have a product portfolio and pipeline
capable of delivering strong future growth."


- Ends -

MLR Bid: 11p Offer: 12p Change: -0.75

yep I must admitt today's figure have beten me. All good news more buys then sells nd the price is marked down.

To me this new deal is like the flotation of a new company and on the figures the price should be more than it is now.

Perheps the old ghosts are still haunting in the minds of old investors, some of whom have been stuck in this one at over 1.60 pounds for years and are sick, sick, sick that Appleby took so much out of the company when leaving, after costing it so much--who knows?

Obviously I dont but I stood by my words and bought today.

But this certainly appears to be an unloved stock---and thoughts please guys.

Good luck all in your endevours to be rich-

hi David .... this stock is far too small to appeal to me, and the chart probably has limited value ..... however, for what it is worth, i paste it below ...... neither 25 nor 50 dma have provided the support one might have hoped, but given that they are now running contangently(?) that may well prove a stubborn resistance as and when sp recovers

Thanks Cynic thats exaclty what has me beat on this one, its doing the opposite to what it should.

Nornally I am not this far out as I love recovery situtations and do well out of them.

I have evey confidence that this will be a whole different ball game in a few months time, but this kind of trading on such good news is difficult to follow.

Thanks again for you input and good luck with your investments.

should perhaps have added that rsi is heavily o'sold and past record indicates it should at least bounce shortly

Would agree with that especially on this news----------Thanks again best wishes.

8 May 2007


Maelor plc ("Maelor" or the "Company")



Director dealings



On 8 May 2007 the Company received notification of the following share purchases
of its 10p Ordinary Shares by Directors:


Name Number of shares purchased Purchase price Total holding at the date of this announcement
Number of ordinary shares % of issued share capital

Geoff McMillan 350,000 10p 850,000 0.68%
Tim Wright 550,000 10p 1,000,000 0.80%
Nigel Goldsmith 550,000 10p 850,000 0.68%
Ann Hardy 100,000 10p 110,000 0.09%
John Gregory 200,000 10p 219,211 0.18%



On 8 May 2007 the Company granted the following share options to the Directors:


Name Number of options Exercise price Date from which options exercisable Expiry date

Geoff McMillan 310,702 10p 8 May 2010 8 May 2017
Tim Wright 3,228,425 10p 8 May 2010 8 May 2017
Nigel Goldsmith 2,235,617 10p 8 May 2010 8 May 2017
Ann Hardy 2,298,117 10p 8 May 2010 8 May 2017
John Gregory 310,702 10p 8 May 2010 8 May 2017
Total 8,383,563

The simplest explanation is surely that the market is adapting to the dilution effect of the 80million new shares issued at 10p - and today is only the first day of the 3 tranches of the 80 million being released to the market - so I suspect a continuation of the fall until a new market is established.

Have got this on my watchlist and may dip my toe for a longer term SIPP type punt in or around the 10p mark - probably below.

could well be if the dilution was not for better things. As it is the dillution has taken the company well into profiablity and in its own right MLR has already stated that its results to March 31 st 2007b will beat market expectations.

For me the dilution is not the answer and its a tough nut to crack

given that the exercise price is 10p, then that would certainly be a logical level at which to buy.

Very logical indeed only the problem with that theory would be the bid falling to around 9p and I cant see that happening, can you?

But if it did I then think so many would top up that it would not stay there for long---so its still worth watching, which is what I am doing right now.

David10B, I have to agree with Cynic and MG. The delivery of new shares, whether created via a placing or via the exercise of options, occurs off the market, so to speak, as the new stock is simply delivered direct to subscribers' accounts by the broker. The lucky holders are presumably selling off today in order to cream off a quick profit. Current SP is : MLR Bid: 10.75p Offer: 11.25p Change: -1.25

So anybody selling shares created as the result of the placing makes an instant 7.5%.

Clearly the bid could drop lower still if the current SP drop frightens a load of other shareholders into selling their holdings, so 9/10p is not out of the question.

Unfortunately there is no cast-iron rule that placings will make the SP go up.

POINT WELL ACCPETED!
And thank you, but clearly this is not the case today. You see there is no massive dumping of shares en bloc, as I write there are 635802 buys 111,416 sells and 131,000 unknowns which are probably buys.

Given that we are creating 90 million new shares at 10p this is a flea bite unless of course there is something lurking.

However even that cant be so as the issues were taken up by directors and insitutions, who when given the massive upside potential of MLR are hardly, in my humble opinion, likely to settle for selling for peanuts in profits.

Sincere thanks for your thoughts and input.

A pleasure, David. I beg to differ regarding volumes traded, as today's is apparently the second biggest trading volume in the past 12 months.

The driver here is not always the number of shares traded as a percentage of those in issue; far rather current volume compared with the average, as well as that old chestnut, supply and demand.

I wouldn't find it unusual if a fund manager decides the fund is a little bit overweight in a stock such is this and goes for skimming the instant profit. It's as well to talk about massive upside potential, but as a fund manager, if you have an instant profit on the table you're likely to make some of it safe, given that these small caps tend to be pretty volatile. Not all of the funds are all that big, either, so if you only have a few million on the market, taking a profit of the odd ten thousand here and there can make a big difference.

Dear Soul traders thank you greatly its really first class and so nice to see a balanced presentation of ones point of view. Obvious you are decent civilised chaps and I welcome discourse with you.

The trades today are smallish, both buys and sells, save one recorded buy of 420000 and an unknown of 120000 the rest, in general, seem to be small the punters getting on board.

Also I note the price seems to easing back up a touch.

Of that does not mean that when the other shares are floated the price wont drift down, but I feel this could be the bottom.

For those long suffering old timers stuck in for years I trust this share will begin to show the good progress I believe that it is capable of.

Thanks again and may good fortune keep smiling on you.

Thanks, David. good luck to you too.

It would appear that MLR is back on course and that as I thought the selling and mark down yesterday was more of a panic nature. However there are still the extra shares to come on to the market today and tomorrow and that means the price could still go either way.

I am plugging for up any comments?

Broker's sentiments 'strong buy' (though it's only one)
http://www.hemscott.com/companies/company-summary.do?companyId=3533

Results should be announced between June 10th and 12th according to the company

I found the following which may be helpful


Date:
1187.2
Page:
Maelor
Circulation:
Aim & Plus Newsletter
01 May 2007

MAELOR
MLR 4.3m 12.5p
REVERSE TAKEOVER / TRADING UPDATE AIM
Maelor, the specialist critical care company, is to be the
subject of a reverse takeover by specialist pharmaceuticals
and devices company, Acorus Therapeutics, in a deal valuing
Acorus at 13 million. The acquisition will be funded
through a mix of cash, shares and loan notes payable over
five years from ongoing cash flow and the total consideration
is subject to certain sales targets. The initial payment
sees the issue of 90 million new shares to institutional
investors which will raise 8 million net. For the year ended
September 30th 2006, Acorus achieved sales of 3 million
(up by 91 %) and operating profits of 0.84 million. The
company will have a market capitalisation of 17 million
after the new shares have been issued.
Meanwhile, a trading statement from the board suggested
that the outcome for the full year to 31st March 2007
will be ahead of market expectations. Positive momentum
gathered in the first half, which pushed turnover up
by 44%, has been sustained through to the final quarter.
Maelor Is well positioned for rapid organic and acquisitive
growth.
COMMENT
This stock has not been our best performer since our tip
at 22.5p in March 2003 - it has fallen by 44% since then
- so it Is pleasing to see some really positive action through
the acquisition of Acorus. The rationale behind the deal Is
clear. Integration costs should be low, due to the virtual
nature of Acorus, making the venture cash-positive from
the outset. Two Acorus products - Mysoline and Cryogesic/
Ethyl Chloride - will contribute to sales immediately and will
soon be followed by several others currently undergoing
registration and trial.
For the year ended 31st March 2007, we expect Maelor to
report revenues of 2.7 million and a pre-tax loss of 0.15
million. However, this news drives clear upgrades and
we now expect the group to be profitable in the current
year to March 2008. Sales of 6.4 million should generate
pre-tax profits of 1.55 million. That equates to earnings
of 1.1 p and, at 12.5p, that puts the stock on a current
year rating of just 11.4 times earnings. Interest payable
from 2009 on the deferred loan notes used to fund Acorus
should be more than compensated for by the significant
increase in cashflow.
There is great earnings potential for Maelor with Acorus'
portfolio of specialist critical care products being highly
synergistic with Maelor's. Opportunities for cross-selling
products to existing customers are clear. Some of Maelor's
products - including Volplex, OptiFlo, Cryogesic and
Mysoline - which have seen significant increases in their
market share, will boost this opportunity. Since undertaking
rigorous evaluation of Maelor's portfolio and competencies
in the latter half of 2005, Tim Wright and his team have
managed to reverse the decline in Maelor's fortunes. With
profits now expected a this year and clear opportunities for
growth, the shares look undervalued. BUY.
.

I did this morning have a great day chaps and keep smiling.

Well no big sell off as some predicted. I see a lift off now from a truly well consolidated base.

Have a great evening chaps, off to the pub tonight---darts.

Well chaps here we are good steady progress from a quality company, run by a second to none first class management team and going just where as my research predicted it would go.

But its far from over yet, there are, I have "sort of" snifted out, some great deals in the pipe line and the share price has a long long way to fly, sorry go, from here.

I have fully researched this company and drawn upon the best confluences of investgative financial resources.

Do yourselves a really big favour and buy some for your wealths sake.

No hard feelings if you dont though as, as ever these decisions are firmly up to you.

Have a great day.

Yep, it's looking good..
If I had some spare dosh I'd top up...otherwise I'm still going to hold as believe these can go a lot higher!

Yes Sir you are so right there.


I could only buy a limited amount today, and then in two sets and could only manage to get them at 14.75p through buying limits, but that was a good sign as the offer then moved to 15p.

Good luck all the way.

Dont think there is need to say anymore now just buy, buy, buy for profit.

30p next stop maybe a bit more.

HOWEVER PLEASE LET THE SP TALK FOR YOU, DONT RUSH IN ON MY THOUGHTS. ALWAYS CONSIDER YOUR INVESTMENT STRATEGY CAREFULLY.

THIS SHARE HAS ONE HECK OF A WAY TO RUN YET AND YOU CAN STILL CATCH IT AT MOST POINTS ON THE WAY UP TO 2 POUNDS STG.

David10B
Well done - should have dipped my toe in instead of waiting for it to get back to 10p. Missed it then but will keep it on my stockwatch - if only to annoy myself :)

Will, however, be looking to add to my SIPP at some stage.

Good call.
mg

The shares mag had a positive article and also in the 'column of director buys in all companys' it shows the three directors buying in.

yes reading other bb's buy orders were hard to fill as from last week

Good luck lads.

Yes, it's looking good...onwards and upwards !

yes I would agree with that of course some people will be sellers as they perhaps do not fully realise or understand the potential massive upside.

Some people bought in at 7p so cashing in for a 100% profit.

Results should be announced between June 10 and 12

Yes I was one of them!

I bought just below 7p, but these shares are now like testicles---you had better hang on to them as they can only go up at the least stimulation.

Chaps I am sure the recent directors' buys were not intended for the SP to stop here.

This company has the hallmark of a major player in the critical care/medical specials field.

I base a lot of confidence in the company, Mr Tim Wright and his team.

I really and honestly believe Mr Wright will at least want to emulate his recent great top class managerial performance at Elan, and at best surpass it.

I see a two pound SP clearly on the horzon with a lot more to come.

For those of you into forward analysis I think you will agree.

And another nice little noche up today despite a very short sighted sale.

This was probably a sale on a 10p buy. Assuming that to be so then thats a 23.400 profit.

Nice some will say.

But in reality hardly worth getting up for when considering the overal potential.

OK a bird in hand maybe worth two in the bushes to some, but seriously chaps for those who fully undertand this new company there are many more birds than bushes.

Have a great evening one and all.

MLR making good headway this morning, please look at, please dont over look it f you want to make a bob or two this week.

Good hunting chaps!

Chaps obviously there is no need for me to ramp this stock here as its doing OK all by itself.

However I still feel there maybe potential buyers out there just a little nervous of getting in.

Ok that is fair enought and besides that who am I?

All I can say chaps is that I have fully researched this stock and its very undervalued.

Get a professional report, turn it insided out and stand it on its head and shake it hard if you wish to, but for Pete's sake if you have had a hard time with the market this year and need to claw back some cash ---BUY this stock!

Its only moving up, as I ahve been telling this BB for weeks, and now as we get closer to the publication of the year end accounts to March 31st its going to go even higher.

I have been watching, and studying this stock for years and conclude its a good 'un and I am more than happy to recommend it ---AND FOR FREE!

Have a great day chaps, if you bought this stock last week it can only get better.

Good TA grapf posted on ADVFN showing the potential of a breakout.

Full acknowledgement to MIKE HARDMAN

http://www.advfn.com/cmn/fbb/thread.php3?id=10990982

Results for year end to March 31st due June 5th. 2007.

They have already stated that they will beat the market's expectations, should see a nice little run up now.

Have a really great day.

BKE seem to be turning the corner...worth a punt.

Great directors...look what they did with COH, from 11P to 50P.

Although they have dropped back a big bounce is on the cards...keep a lookout.

Its always great to have other's view points for the sake of the shareholders I sincerely trust that you are right.

The in the SP of COH since it consolidated has made many shrewd punters a lot of money and as the SP has bottomed since the recent sell-off, there are more profits to be made in the coming months.

RE COH.

As stated its always nice to have a diverse of views on shares.

I have no doubt COH has made money for many and good for them.

Anyone beating the market gets top marks from me.

However its not those that concern me.

In times like this its the poor sods that are now firmly stuck fast, having bought in, as they did, at around 50p.

I simply feel the the Chairman should make some announcement, how ever brief, in order to illuminate the situation as, and I trust you have noticed COH sellers are still quite strong.

If today's mid-price trades where buys then there could be more buys than sells and as the SP did not move then IMHO they were buys.